MMP9 and Stroke: Inhibitors of PARP-1, namely JPI-289, FR247304, and MP-124, significantly maintained the TJs and reduced the MMP9 levels, brain swelling, HT occurrence, infarction size, and functional deficiency in stroke (274, 276, 277).